Sail Biomedicines is pioneering advancements in programmable medicines through its innovative platform that integrates Endless RNA™ (eRNA™) technology and proprietary programmable nanoparticles. The eRNA™ technology represents a new class of synthetic RNA that is translatable and stable, allowing for the expression of diverse proteins within the body with long-lasting effects. This capability significantly enhances the therapeutic potential of RNA medicines, addressing unmet patient needs and expanding treatment options for various diseases. Additionally, Sail's Natural NanoParticle (NNP) technology utilizes a unique "routing code" derived from nature, enabling targeted delivery of therapeutics to specific cells and tissues, which is crucial for maximizing efficacy and minimizing side effects.

The company leverages artificial intelligence (AI) and rapid prototyping to optimize the design and delivery of its RNA medicines. By employing proprietary AI algorithms, Sail can analyze vast amounts of data to refine its therapeutic approaches, ensuring that medicines are delivered to the right cells at the appropriate doses. This comprehensive programming of medicines not only enhances their effectiveness but also aims to provide a safer and more tolerable treatment profile compared to existing nucleic acid technologies. Overall, Sail Biomedicines is at the forefront of a new era in medicine, focusing on creating durable, effective, and targeted therapies for oncology, metabolic diseases, infectious diseases, rare diseases, and immunology.

United States

We work at the frontier of programmable medicines. We power our bioplatform and product candidates by harnessing evolution and AI. We operate with purpose and urgency on behalf of people everywhere. We aim to generate life-changing impact for the world.

Sail Biomedicines

Company Details